• Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research
    Jan 13 2026

    How has immunotherapy evolved in the last decade? In this episode of The Chain, Laszlo Radvanyi, professor of immunology at the University of Toronto, discusses his years-long research on cancer immunotherapy, including his time at MD Anderson, with host Rakesh Dixit. He shares his thoughts on agonist antibodies, the true breakthroughs that are moving the needle for patients, reducing the CD-28 pathway so that it doesn’t produce cytokine toxins, and what is the next frontier in immunotherapy.

    Links from this episode:
    EpiVax
    University of Toronto, Department of Immunology
    University of Toronto

    Show More Show Less
    44 mins
  • Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity
    Dec 9 2025

    December 13, 2025 | What is next for immunogenicity? In this episode of The Chain, Vibha Jawa, chief scientific officer at EpiVax, provides her thoughts and insights on BiTE molecules, pegylated molecules, and other biologic molecules and their impact on cancer treatment and research with host Rakesh Dixit. Jawa shares the most rewarding project she’s worked on and what therapeutic modality she sees being picked up in the next decade, as well as advice for the next generation of scientists, such as why it’s important to be hands-on with research and be collaborative with others.

    Links from this episode:
    EpiVax

    Show More Show Less
    27 mins
  • Episode: 79 - Conversation with Bahija Jallal on the Biggest Anticipated Transformations and Breakthroughs
    Nov 11 2025

    November 11, 2025 | What is the next modality to focus on in the next 10 years? For Bahija Jallal, CEO of Immunocore, it would be T-cell engagers. In this episode of The Chain, host Rakesh Dixit speaks with Jallal on the potential advantages of bispecific T-cell engager therapy versus T-cell receptor therapy, biggest anticipated changes in drug discovery and development in the next 10 years, and how AI is going to impact the next generation of scientists. Plus, Jallal shares her experiences as the previous president of MedImmune and at AstraZeneca, what her most rewarding project was, and the transformations and achievements that occurred under her leadership.

    Links from this episode:
    Immunocore

    Show More Show Less
    43 mins
  • Episode: 78 - Shamit Shrivastava on an Interdisciplinary Approach to Antibody Biophysics and Developability
    Oct 14 2025

    As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into Liquid Brain, his interdisciplinary innovation that’s changing the way researchers tackle developability of challenging antibody-based drugs. Shamit breaks down what makes Liquid Brain different from traditional developability methods, reveals how it’s unlocking new possibilities for complex format development, and shares a glimpse into Apoha’s future-including an exclusive preview of what’s coming at PEGS Europe this November.

    Show More Show Less
    34 mins
  • Episode: 77 - Derek Lowe on AI and the US Biotech Ecosystem
    Sep 16 2025

    September 16, 2025 | With the rise of AI and automation, what is the core human skill in drug discovery that is and will be valuable in the future? Derek Lowe, director of Chemical Biology Therapeutics at Novartis and author of the In the Pipeline blog, discusses the impact of AI—and non-AI technologies—on the business of drug making. With host Christopher Bahl, cofounder and CEO of AI Proteins, their conversation covers the value of a PhD in the tech world today, the long-term impacts of knowledge creation in US leadership positions, how the industry can navigate a biotech winter, and more.

    Links from this episode:
    AI Proteins
    Novartis
    In the Pipeline

    Show More Show Less
    42 mins
  • Alexey Lugovskoy Shares Decades of Experience in Starting Out and Founding Companies
    Aug 12 2025

    August 12, 2025 | Diagonal Therapeutics founder and CEO Alexey Lugovskoy discusses the key lessons learned over his illustrious career, starting from his childhood in the Soviet Union to founding his own company, Diagonal Therapeutics. With host Tariq Ghayur, Lugovskoy shares insights gained from working with organizations of different sizes, taking on the obstacles of building a pipeline, and integrating AI/ML into discovery programs, as well as his most memorable achievement—and most memorable failure. He also offers advice to young scientists and entrepreneurs, emphasizing the importance of challenging problems and surrounding yourself with the right people.

    Show More Show Less
    47 mins
  • Episode: 75 - Are Licensing Fees Required or Gatekeeping?
    Jul 29 2025

    July 15, 2025 | Are licensing fees required or gatekeeping? In this episode of The Chain, host Nimish Gera, vice president of Biologics at Mythic Therapeutics, and Ian Wilkinson, CEO of Gamma Proteins, discuss accessing antibody discovery technology through licensing fees and royalties—and whether these fees are justified or not. Wilkinson delves into the current landscape of antibody discovery technologies, including if AI-based technology warrants fees, how royalties affect both small companies and big pharma, and his background as one of the first experts in the field who offered purely free-for-service options. He also shares what excites him about antibody engineering and beyond.

    Links from this episode:

    Mythic Therapeutics
    Gamma Proteins

    Show More Show Less
    33 mins
  • Episode: 74 - Keith Flaherty, President-Elect of AACR, on Public and Private Collabs, AI Optimism, and More
    Jun 11 2025

    June 10, 2025 | In this bonus episode of The Chain, Daniel Chen, MD, PhD, founder and CEO of Synthetic Design Lab, returns for the Science Commune segment and speaks with Keith Flaherty, MD, FAACR, professor of Medicine of Harvard Medical School and president-elect of AACR. They discuss Flaherty’s prolific career; how his background led him to pursue a career in medicine; how public and private sectors are coming together in oncology around collaborations; reflections on targeted therapies and technologies; optimism around how AI will impact society and the future of medicine positively; and how we need to detect and treat disease early.

    Links from this episode:

    PEGS Boston Conference & Expo

    Engineering Bispecific Antibodies

    Synthetic Design Lab

    Harvard Medical School

    AACR

    Show More Show Less
    47 mins